Elixirgen Therapeutics
Shinichiro Okamoto, MD, Ph.D., graduated from the School of Medicine at Keio University in 1979 and received a Ph.D. from Keio University in 1983. From 1985 to 1988, Dr. Okamoto worked as a research/clinical fellow at the Division of Hematology/Oncology, Emory University in Atlanta, and as a visiting clinical fellow at the Fred Hutchinson Cancer Research Center in Seattle. After his training in the U.S., He came back to Keio University and has continued to work in the field of hematopoietic cell transplantation until now. He is currently the Chairman and Professor of Medicine, Department of Medicine at Keio University, and the Director of Hematology Service at Keio University Hospital in Tokyo.
In addition to his work at Keio University, Dr. Okamoto contributed a lot to promote the activity of hematopoietic cell transplantation (HCT) in Japan. He has been working for Japan Society for Hematopoietic Cell Transplantation (JSHCT) as a Board member since 2004. In 2012 Dr. Okamoto became the Chairman of the Board Members, JSHCT, and continues to lead the Society. He has also been working for Japan Marrow Donor Program (JMDP) as the Chairman of the International Committee and the Board member since its establishment in 1992.
From 1999 to 2005, he also served as the Vice President of the World Marrow Donor Association (WMDA) and the Chairman of the Accreditation Committee. He served as a member of the Advisory Committee, CIBMTR from 2012 to 2014. Dr. Okamoto has been leading the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) as the Chairman of the Board of Directors. He is also one of the founding members of the Society. Through those activities, Dr. Okamoto has been contributing to not only fostering the activity of HCT in Asia-pacific countries but also collaboration and harmonization of the global activity of HCT.
This person is not in the org chart
This person is not in any offices
Elixirgen Therapeutics
Elixirgen Therapeutics is a biotechnology company focused on curing humanity’s ailments through stem cell biology.